Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10508307
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
granted -
US 10508122
Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
granted -
US 10508140
Peptide having hair growth-promoting activity and/or melanin generation-promoting activity, and use thereof
granted -
US 10507239
V1/V2 fragments of a HIV-1 envelope glycoprotein
granted -
US 10507284
Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type I diabetes applications
granted -
US 10508129
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
granted -
US 10500194
Covalent small molecule DCN1 inhibitors and therapeutic methods using the same
granted -
US 10500256
Polymers for delivery of therapeutic proteins
granted -
US 10500290
Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer
granted -
US 10501490
Taccalonolide microtubule stabilizers
granted -
US 10501538
Anti-LILRB antibodies and their use in detecting and treating cancer
granted -
US 10501575
Biomimetic fluoroscopic films
granted -
US 10500271
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
granted -
US 10501816
Compositions and methods for detecting human pegivirus 2 (HPgV-2)
granted -
US 10501800
Breast cancer prognosis
granted -
US 10500177
Glutarate compounds for treating ischemia-reperfusion injuries
granted -
US 10494612
Adeno-associated virus virions with variant capsid and methods of use thereof
granted -
US 10493038
Formulation of acoustically activatable particles having low vaporization energy and methods for using same
granted -
US 10494405
Methods and compositions for the treatment of arthritis
granted -
US 10494619
High isomerohydrolase activity mutants of human RPE65
granted -
US 10494401
LLP2A-bisphosphonate conjugates for osteoporosis treatment
granted -
US 10493037
Multiphasic particles fabricated by wettability engendered templated self-assembly (WETS) methods
granted -
US 10493098
Mesoporous silica-coated nanoparticles
granted -
US 10494402
Peptides that stimulate subcutaneous adipogenesis
granted -
US 10493162
Somatostatin receptor-based cancer therapy
granted -
US 10485809
Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
granted -
US 10487148
Methods and compositions for treating aging-associated impairments
granted -
US 10488416
Targeting breast cancer therapy based on stromal subtypes and CD146 composition
granted -
US 10485829
Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
granted -
US 10485774
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 10487341
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10487054
Therapeutic compounds
granted -
US 10487113
Peptide having activity to improve skin condition and use thereof
granted -
US 10485886
Core-satellite nanocomposites for MRI and photothermal therapy
granted -
US 10485800
Mixed lineage kinase inhibitors for HIV/AIDS therapies
granted -
US 10478206
Instruments and methods for the implantation of cell-seeded substrates
granted -
US 10478513
Nitroxide containing amyloid binding agents for imaging and therapeutic uses
granted -
US 10478505
Edible oils to enhance delivery of orally administered steroids
granted -
US 10478508
Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
granted -
US 10479839
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
granted -
US 10479825
Antibody-mediated neutralization of Marburg virus
granted -
US 10478461
Cellular extracts
granted -
US 10478485
Methods and compositions to prevent or treat bacterial infections
granted -
US 10478404
Materials, methods and devices for altering cell reactivity
granted -
US 10471134
Enzymes and methods for cleaving N-glycans from glycoproteins
granted -
US 10472330
Substituted triazenes protected from degradation by carboxylation of N1
granted -
US 10472340
Substituted phenothiazines as mitochondrial agents
granted -
US 10472346
Potent gamma-secretase modulators
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory